CLONING, EXPRESSION AND PURIFICATION OF TOXOPLASMA GONDII HSP90 N DOMAIN

Dovilė Daunoraitė1, Marius Gedgaudas1, Aurelija Mickevičiūtė1, Daumantas Matulis1, Egidijus Kazlauskas1

1 Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Parasitic protozoan diseases affect millions of people worldwide causing severe morbidity and mortality. These diseases include malaria, leishmaniasis, toxoplasmosis and cause over a million deaths every year. It is estimated that billions of people may be infected with some form of protozoan parasite. As parasites quickly develop resistance mechanisms, many drugs have become ineffective. Furthermore, many of the current drugs have unacceptable side effects. Therefore there is an urgent need to develop novel treatments against parasitic protozoan diseases [1]. Toxoplasma gondii, which is the main subject of our research, causes oportunistic infection to immunocompromised hosts such as HIV patients. The most acute form of the disease is toxoplasmic encephalitis that often lead to fatal outcome [2].

Heat shock protein 90 (Hsp90) is a highly conserved dimeric molecular chaperone. It is essential for eukaryotic cells and is involved in various key pathways ensuring correct folding, maturation and degradation of select client proteins. Healthy human cells are significantly less sensitive to partial Hsp90 inhibition than parasitic protozoa, which depend on the chaperone to adapt to stressful conditions during infection. This makes Hsp90 an attractive drug target against these diseases [2, 3].

Our aim is to develop drugs based on Hsp90 inhibition to treat protozoan diseases. One of the first challenges is the acquisition of a viable target protein model for ligand binding experiments. As full length proteins are often hard to obtain and are unsuitable for some of the experimental techniques, we chose to work with the isolated N-terminal domain of Hsp90 (Hsp90N), which binds ATP and most of the Hsp90-selective inhibitors [4]. However, protozoan Hsp90N tend to misfold. Here we suggest that addition of a short (4-5 aa long) complementary β-sheet is necessary for the correct folding of Toxoplasma gondii Hsp90N, when expressed in Escherichia coli. This β-sheet can be successfully adopted from homologous Hsp90N of Plasmodium falciparum [5]. Protein stability was assessed using fluorescence thermal shift assay and correct active site folding was confirmed by binding studies with Hsp90N ligands.


[1] Fletcher, Stephanie M., et al. "Enteric protozoa in the developed world: a public health perspective." Clinical microbiology reviews 25.3 (2012): 420-449.

[2] Addmore, et al. "Intracellular protozoan parasites of humans: the role of molecular chaperones in development and pathogenesis." Protein and peptide letters 18.2 (2011): 143-157.

[3] Schopf, Florian H., Maximilian M. Biebl, and Johannes Buchner. "The HSP90 chaperone machinery." Nature Reviews Molecular Cell Biology (2017).

[4] Gewirth, Daniel T. "Paralog specific Hsp90 Inhibitors–a brief history and a bright future." Current topics in medicinal chemistry 16.25 (2016): 2779.

[5] Corbett, Kevin D., and James M. Berger. "Structure of the ATP-binding domain of Plasmodium falciparum Hsp90." Proteins: Structure, Function, and Bioinformatics 78.13 (2010): 2738-2744.